Evidence map›Paper›PMID 33753374›Full record

ArticleCancer research2021

GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy.

Pierre-Benoit Ancey, Caroline Contat, Gael Boivin, Silvia Sabatino, Justine Pascual, Nadine Zangger, Jean Yannis Perentes, Solange Peters, E Dale Abel, David G Kirsch and 3 more

Abstract read
In one paragraph

Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

123 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Direct targeting of GLUT1 in cancer: A decade of inhibitor discovery and medicinal chemistry insights.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Pierre-Benoit AnceySwiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Caroline ContatSwiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Gael BoivinSwiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Silvia SabatinoSwiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Justine PascualSwiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Nadine ZanggerSwiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.ORCID 0000-0002-9347-7929
Jean Yannis PerentesSwiss Cancer Center Léman, Lausanne, Switzerland.
Solange PetersSwiss Cancer Center Léman, Lausanne, Switzerland.ORCID 0000-0002-0412-7143
E Dale AbelFraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Carver College of Medicine, University of Iowa, Iowa City, Iowa.ORCID 0000-0001-5290-0738
David G KirschDepartment of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0002-2086-205X
Jeffrey C RathmellVanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, Tennessee.
Marie-Catherine VozeninSwiss Cancer Center Léman, Lausanne, Switzerland.
Etienne Meylan *Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland. etienne.meylan@epfl.ch.ORCID 0000-0002-0899-2230

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
Advancing Cancer Therapy through Ground Breaking Research in Radiation BiologyR35CA197616 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI David Guy Kirsch · 2016 to 2026
$10.7M
NCI NIH HHS P30 CA014236NCI NIH HHS R35 CA197616
6 · The paper itself

Abstract

Neutrophils are the most abundant circulating leucocytes and are essential for innate immunity. In cancer, pro- or antitumor properties have been attributed to tumor-associated neutrophils (TAN). Here, focusing on TAN accumulation within lung tumors, we identify GLUT1 as an essential glucose transporter for their tumor supportive behavior. Compared with normal neutrophils, GLUT1 and glucose metabolism increased in TANs from a mouse model of lung adenocarcinoma. To elucidate the impact of glucose uptake on TANs, we used a strategy with two recombinases, dissociating tumor initiation from neutrophil-specific

Indexed as

Treatment FailureAdenocarcinoma of LungAnimalsCase-Control StudiesCell Line, TumorCell ProliferationCell SurvivalDisease Models, AnimalGlucose Transporter Type 1HumansLung NeoplasmsMiceMice, Inbred C57BLMice, KnockoutNeutrophilsTumor MicroenvironmentGlucose Transporter Type 1SLC2A1 protein, humanSlc2a1 protein, mouse

Identifiers

PMID33753374
PMCPMC8137580

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.